Skip to main content
OpenTrials
Completed

NCT Number: NCT03262883

The Prevalence of Chronic Critical Illness in Turkey

It is known that the number of Chronic Critical İllnes, an iatrogenic condition, increases all over the world. The prevalence of Chronic Critical Illness in Turkey is unknown. The investigators aimed to evaluate the etiology, comorbid conditions, demographic data, prevalence, mortality and costs of these patient in intensive care units in Turkey. In this multi-centered study, The investigators will retrospectively review the last 1 year of patients receiving treatment at the Adult Intensive Care Unit.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Yuzuncu Yıl University

Van, 65080, Turkey (Türkiye)

About this study

The patients who survive an acute critical illness in the Intensive Care Unit (ICU) may be delayed in a situation where they are sometimes totally independent before hand due to iatrogenic causes such as infections, dysfunctions, psychological disorders. This can take weeks, sometimes months. This disease is called "Chronic Critical Illness" (CCI).

Most researchers associate CCI with the need for prolonged acute mechanical ventilation or the opening of tracheostomy for prolonged acute mechanical ventilation. There is no single condition that does not require an extended mechanical ventilation from CCI. In conclusion, CCI is characterized by long-term care requiring survival and it is predicted that the cost of these patients will increase with the new patients whose cost will be added in the coming years. In the United States, the number of CCI is around 250,000, and this figure has increased by 50-100% in the last 10 years. At least 50% of these patients die in one year and less than 12% recover and become discharged. The annual cost of these patients' health care system is over $ 20 billion. The prevalence of CCI in Turkey is still unknown. In this study, it was aimed to investigate the prevalence of patients with Chronic Critical Syndrome in intensive care units in Turkey.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The patient who is over 18 years old, taking mechanical ventilation support and staying in the critical care unit at least 8 days. Additional criterias; Clinical diagnosis of following situations:

  • Prolonged mechanical ventilation
  • Tracheotomia
  • Sepsis
  • Serious injury (burn)
  • Stroke ( hemorhagic or ischemic)
  • Traumatic brain injury

Exclusion criteria

  • The patients who not having mechanical ventilation support
  • The patient staying less than 8 days in the intensive care unit
  • The patient younger than 18 years old

Treatment and study plan

Primary outcomes

  1. Critical care unit mortality

    Time frame: 30 day and 90 day

    The mortality change rates in the 30th days and 90th days

Secondary outcomes

  1. Critical care unit costs

    Time frame: Duration of intensive care unit stay (8 day after the hospitalisation to sixth month)

    Costs of patients staying in the intensive care unit

Sponsors and collaborators

Lead sponsor

Yuzuncu Yil University

Other

Collaborators

  • Izmir Ataturk Training and Research Hospital
  • Kahramanmaras Sutcu Imam University

Registry information

Official study title

The Prevalence of Chronic Critical Illness Adult Intensive Care Units in Turkey

Important dates

Study start
2017
Primary completion
2018
Study completion
2019
First posted
Aug 25, 2017
Registry last updated
Oct 10, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.